Perrigo Co. announced that it has made initial shipments distributing Cumberland Pharmaceuticals Inc.'s Authorized Generic form of Acetadote(R) (acetylcysteine) injection. The Authorized Generic is free of EDTA and any other chelating, stabilization or preservative agents.

On November 13, 2012, Perrigo announced that it and Cumberland had successfully settled their patent litigation. In addition, Perrigo secured the right to be a distributor should Cumberland elect to launch an Authorized Generic acetylcysteine injection product. Acetadote(R) (acetylcysteine) injection, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury and has annual sales of approximately $41 million, as measured by Symphony Health Solutions.